Literature DB >> 11231381

Recent developments in the management of secondary hyperparathyroidism.

W G Goodman1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11231381     DOI： 10.1046/j.1523-1755.2001.0590031187.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


× No keyword cloud information.
  20 in total

1.  The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.

Authors:  Naro Ohashi; Toshihiko Uematsu; Satoru Nagashima; Mitsutaka Kanamaru; Akashi Togawa; Akira Hishida; Eiji Uchida; Tadao Akizawa; Shozo Koshikawa
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 2.  Renal osteodystrophy for nonnephrologists.

Authors:  William G Goodman
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 3.  Management of musculoskeletal complications in endstage renal disease: an update.

Authors:  Dharmarajan Ramaswamy; Petros Efthimiou; Isaiarasi Gnanasekharan; Anita Soni
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

4.  Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.

Authors:  Desmond Padhi; Robert Harris; John T Sullivan
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

Review 5.  Current advances in chronic kidney disease in children: growth, cardiovascular, and neurocognitive risk factors.

Authors:  Larry A Greenbaum; Bradley A Warady; Susan L Furth
Journal:  Semin Nephrol       Date:  2009-07       Impact factor: 5.299

6.  Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.

Authors:  Takashi Shigematsu; Tadao Akizawa; Eiji Uchida; Yusuke Tsukamoto; Manabu Iwasaki; Shouzo Koshikawa
Journal:  Am J Nephrol       Date:  2008-09-17       Impact factor: 3.754

7.  The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.

Authors:  Piergiorgio Messa; Fernando Macário; Magdi Yaqoob; Koen Bouman; Johann Braun; Beat von Albertini; Hans Brink; Francisco Maduell; Helmut Graf; João M Frazão; Willem Jan Bos; Vicente Torregrosa; Heikki Saha; Helmut Reichel; Martin Wilkie; Valter J Zani; Bart Molemans; Dave Carter; Francesco Locatelli
Journal:  Clin J Am Soc Nephrol       Date:  2008-01       Impact factor: 8.237

Review 8.  Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.

Authors:  William G Goodman
Journal:  Pediatr Nephrol       Date:  2003-10-28       Impact factor: 3.714

9.  Factors associated with low bone mass in the hemodialysis patients--a cross-sectional correlation study.

Authors:  Guey-Shiun Huang; Tzong-Shinn Chu; Meei-Fang Lou; Shiow-Li Hwang; Rong-Sen Yang
Journal:  BMC Musculoskelet Disord       Date:  2009-06-04       Impact factor: 2.362

10.  Effect of vitamin D supplementation versus placebo on essential hypertension in patients with vitamin D deficiency: a double-blind randomized clinical trial.

Authors:  Vida Sheikh; Azadeh Mozaianimonfared; Mohsen Gharakhani; Jalal Poorolajal
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-20       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.